BioCentury co-founder succeeds Wain Fishburn, effective July 1Continue reading
Category Archives: AZBio News
TGen scientists identify nanobody that can be engineered to clear Alzheimer’s plaques
Fusion antibody was comparable to aducanumab treatment in clearing amyloid plaques in mice
AZBio Member Spotlight – Translational Genomics Research Institute (TGen), part of City of Hope
Based in Phoenix, Arizona, TGen’s mission is to translate research discoveries into improved diagnostics and therapies, shortening the path from scientific discovery to improved patient outcomes.Continue reading
How do different dementia pathologies interact in the mouse brain?
TGen-led study clarifies interactions between amyloid, tau, alpha-synuclein proteins
C-Path Awards $250,000 Grant to Advance New Treatment for Sepsis-Associated Neurocognitive Dysfunction
TUCSON, Ariz., July 9, 2026 — Critical Path Institute® (C-Path) has awarded a $250,000 research grant to Teresa Sanchez, Ph.D., of Weill Cornell Medicine, to support the development of a novel therapeutic approach for sepsis-associated neurocognitive dysfunction.Continue reading
Partnership Creates a Bridge Between Arizona and Taiwan Life Science Communities
The Arizona Bioindustry Association, Inc. (AZBio) and Bio Taiwan execute a Memorandum of Understanding focused on fostering collaborations between organizations in the Arizona and Taiwan life science sectors at the 2026 BIO International Convention in San Diego.
AZBio Member Spotlight – Valley Fever Solutions
Based in Arizona, Valley Fever Solutions is focused on resolving valley fever and from there, expanding to treat fungal infections more broadly, with a vision to redefine treatment standards in fungal disease.Continue reading
AZBio Member Spotlight – ImmunoShield Therapeutics
Based in Arizona, ImmunoShield Therapeutics is working to turn the long-promised curative potential of allogeneic cell therapies into a reality, starting with type 1 diabetes.Continue reading
GT Medical Technologies Completes Oversubscribed $100 Million Series E Equity Financing to Advance Commercial Treatment for Patients with Operable Brain Tumors
Financing round led by new investor Viking Global Investors with participation from key existing investorsContinue reading
C-Path Reaffirms Commitment to Advancing Regulatory Science for Disease-Modifying Therapies in Type 1 Diabetes
Regulatory milestone underscores opportunity for shared regulatory-science and evidence frameworks to support the next generation of therapies.Continue reading